Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 18/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14055208 | 0.82 | EGLN1 (0.49) | GCGRMAPK1 | |
| SCHEMBL14054702 | 0.81 | GCGR (0.71) | GCGR | |
| SCHEMBL5937430 | 0.78 | EGLN1 (0.57) | MAPK1 | |
| SCHEMBL3298353 | 0.77 | NPC1 (0.42) | GCGR | |
| SCHEMBL29752442 | 0.75 | ABL1 (0.54) | — | |
| SCHEMBL942693 | 0.75 | ABL1 (0.54) | — | |
| SCHEMBL769167 | 0.74 | MAPK1 (0.65) | MAPK1 | |
| SCHEMBL31368564 | 0.74 | MAPK1 (0.65) | MAPK1 | |
| SCHEMBL26971178 | 0.73 | MAPK1 (0.42) | MAPK1 | |
| SCHEMBL4218916 | 0.72 | CYP4F2 (0.49) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2714661-B1 | PICOLINAMIDO - PROPANOIC ACID DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-30 | — | — | EP | disclosed |
| US-8748624-B2 | Picolinamido-propanoic acid derivatives useful as glucagon receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-10 | — | — | US | disclosed |
| WO-2012162407-A1 | PICOLINAMIDO - PROPANOIC ACID DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2012-11-29 | — | — | WO | disclosed |
| US-20120302610-A1 | PICOLINAMIDO-PROPANOIC ACID DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2012-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302610-A1 | PICOLINAMIDO-PROPANOIC ACID DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | GLP1R, GIPR, GCGR | GCGR 3/4885MAPK1 2085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.